• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: J&J’s Cerenovus to discontinue Codman liver cancer pump

April 26, 2018 By Fink Densford

Johnson & Johnson

Johnson & Johnson‘s (NYSE:JNJ) Cerenovus is discontinuing production of its Codman pumps designed to deliver targeted chemotherapy to the liver for patients with liver cancer, according to a New York Times report.

The devices are designed to be implanted in the abdomen to deliver chemotherapy directly to the liver to treat cancer that has spread to the area, generally from the colon or rectal tumors, according to the report.

Johnson & Johnson is reportedly ending production due to “significant and multiple raw material supply constraints within the manufacturing process,” according to the Times.

Patients at Memorial Sloan Kettering who received the pump lived approximately two years longer than those who did not get the therapy, according to the report, which cited a study of 2,368 patients with colorectal cancer.

The company only sold approximately 300 units a year, but the units can be essential to the survival of patients with liver cancer, according to the report.

“Now I have to decide who gets this potentially lifesaving therapy,” Dr. Ryan Merkow of Northwestern University told the Times.

Other practitioners shared similarly difficult stories of choices being made based on the discontinuation of the devices, including a number of postponed and cancelled operations for patients with little to no options otherwise.

“Unfortunately, some of the suppliers that provide the materials, such as titanium rods needed for production of these pumps, have elected to exit the business or have found that the required materials are no longer available,” J&J Cerenovus spokesman Mindy Tinsley told the Times.

Johnson & Johnson said that it is still pursing alternatives, though would not say what they were.

Competitor Medtronic (NYSE:MDT) produces a similar pump, according to the report, but is designed for use with the spine and lacks a catheter used with the Codman pump.

Filed Under: Featured, Implants, Oncology Tagged With: johnsonandjohnson, Medtronic

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS